After giving the fund some time to perform, INN spoke with Hawkins again to discuss its movement and the interest investors have shown in psychedelics. Hawkins remains bullish on the long-term impact of the entire psychedelics industry, particularly the potential benefits of widely available medical products to help growing mental health concerns. “We’re still very excited about what psychedelics can do and the effect it can have on our entire social ecosystem with respect to curing people or helping people with their mental illnesses,” Hawkins said during the video conversation. The ETF executive credited the initial wave of excitement surrounding the sector to a massive amount of self-generated interest from retail investors, alongside the generous launch of new companies pursuing the space. “There was a lot of investor interest in getting into this sector pretty early,” he said.